Upcoming regulatory changes to create new opportunity for specialized offerings.
Mark Trusheim
Advertisement
Articles by Mark Trusheim
Pharmaceutical Executive
An overview of Orphan Reinsurer and Benefit Managers groups, including potential challenges with the model and various model suggestions.
Advertisement
Latest Updated Articles
Improving Management of Gene and Cell TherapiesSeptember 10th 2018
Advertisement
Advertisement
Trending on PharmExec
1
U.S. Supreme Court Unanimously Votes in Favor of Hikma in Case Against Amarin: Report
2
Chai Discovery Enters License Agreement with Pfizer to Accelerate Drug Discovery with AI
3
Alnylam Enters $2 Billion Strategic AI Collaboration with Inceptive
4
New FDA Draft Guidance Targets Gene Therapy Submission Burden by Allowing Use of Existing CMC and Scientific Knowledge
5